Tara N. Ellingson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tara N. Ellingson has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Julio C. Rojas
Edward and Pearl Fein Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
2 shared publications - Lawren VandeVrede
Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, USA
2 shared publications Allen Song
Brain Imaging and Analysis Center, NC; and
1 shared publicationAnne Marie Rodriguez
Department of Neurology, UCSF Weill Institute for Neurosciences, University of California-San Francisco, CA
1 shared publicationBrandon Chan
Department of Neurology, UCSF Weill Institute for Neurosciences, University of California-San Francisco, CA
1 shared publicationChris Petty
Brain Imaging and Analysis Center, NC; and
1 shared publication
Latest Publications
- Open Access
When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy
Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (TRAC). We compared Centiloid quantitation across pipelines and visual reads for interpreting pre– and post-ATT amyloid PET. Methods : We analyzed 18F-florbetapir or 18F-florbetaben PET from 101 patients treated with lecanemab or donanemab: 88 pre-ATT and 54 post-ATT scans, including 41 paired scans. Centiloids were derived using FDA-cleared MIMneuro and two research pipelines (rPOP, CapAIBL) and compared using intraclass correlation coefficients (ICC). Clearance rates were estimated using linear mixed-effects models. Full TRAC was defined on post-ATT scans quantitatively (Results : Treated patients were 74±7 years old; 57% were female, 59% were apolipoprotein E ε4 carriers, and 78% had mild cognitive impairment (22% mild dementia). Centiloid agreement between pipelines was equally high pre– and post-ATT (both ICCs=0.90). Among paired scans (mean treatment duration, 16.7±4.6 months), clearance estimates were similar across pipelines and greater with donanemab (n=15 patients; between –62 and –60 Centiloids/year depending on the pipeline) than lecanemab (n=26; –38 to –36 Centiloids/year; all PConclusion : Centiloid quantitation was robust across pipelines before and after ATT initiation, yielding clearance rates consistent with clinical trials. However, quantitative and visual assessments were markedly discordant after ATT, with an unusually high proportion of scans <11 Centiloids remaining visually positive, warranting cautious interpretation of post-ATT Centiloid values. Larger studies should assess the clinical relevance of these findings and further develop robust approaches to establish full TRAC.
Open AccessWhen Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy
Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (TRAC). We compared Centiloid quantitation across pipelines and visual reads for interpreting pre– and post-ATT amyloid PET. Methods : We analyzed 18F-florbetapir or 18F-florbetaben PET from 101 patients treated with lecanemab or donanemab: 88 pre-ATT and 54 post-ATT scans, including 41 paired scans. Centiloids were derived using FDA-cleared MIMneuro and two research pipelines (rPOP, CapAIBL) and compared using intraclass correlation coefficients (ICC). Clearance rates were estimated using linear mixed-effects models. Full TRAC was defined on post-ATT scans quantitatively (Results : Treated patients were 74±7 years old; 57% were female, 59% were apolipoprotein E ε4 carriers, and 78% had mild cognitive impairment (22% mild dementia). Centiloid agreement between pipelines was equally high pre– and post-ATT (both ICCs=0.90). Among paired scans (mean treatment duration, 16.7±4.6 months), clearance estimates were similar across pipelines and greater with donanemab (n=15 patients; between –62 and –60 Centiloids/year depending on the pipeline) than lecanemab (n=26; –38 to –36 Centiloids/year; all PConclusion : Centiloid quantitation was robust across pipelines before and after ATT initiation, yielding clearance rates consistent with clinical trials. However, quantitative and visual assessments were markedly discordant after ATT, with an unusually high proportion of scans <11 Centiloids remaining visually positive, warranting cautious interpretation of post-ATT Centiloid values. Larger studies should assess the clinical relevance of these findings and further develop robust approaches to establish full TRAC.
- 1 September 2025
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 1 (3)
Cognitive Impairment in Liver Transplant Recipients
- 1 September 2025
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 1 (3)
Cognitive Impairment in Liver Transplant Recipients